Gene: Apoe (apolipoprotein E)  Rattus norvegicus Symbol: Apoe Name: apolipoprotein E Description: ENCODES a protein that exhibits beta-amyloid binding; hydroxyapatite binding; lipid transporter activity; INVOLVED IN aging; cellular response to cholesterol; cellular response to growth factor stimulus; PARTICIPATES IN altered lipoprotein metabolic pathway; lipoprotein metabolic pathway; Alzheimer disease pathway; ASSOCIATED WITH Alzheimer Disease; Diabetes Mellitus, Experimental; Glomerulonephritis, Membranous; FOUND IN cytoplasm; dendrite; early endosome; INTERACTS WITH 17alpha-ethynylestradiol; 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine; 3H-1,2-dithiole-3-thione Type: protein-coding RefSeq Status: VALIDATED Also known as: apo-E; APOEA; apolipoprotein E Orthologs: Homo sapiens : APOE (apolipoprotein E)  HGNC Mus musculus : Apoe (apolipoprotein E)  MGI Allele / Splice: Apoeem8Mcwi   Apoeem7Mcwi   Latest Assembly: RGSC Genome Assembly v3.4 Position: Map Chr Position Strand Source Rat Cytogenetic Map 1 q21   NCBI RGSC Genome Assembly v5.0 1 81,878,372 - 81,881,125 - NCBI RGSC Genome Assembly v3.4 1 79,003,634 - 79,006,387 - NCBI Rat Celera Assembly 1 73,813,122 - 73,815,875 - NCBI Genome Assembly 3.1 1 79,081,854 - 79,083,684 - NCBI Model Launch Genome Browser (GBrowse) Annotation    (Toggle Detail/Summary View) Disease Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) Alzheimer Disease   ISS RGD:736387 6903910 protein:increased expression:parietal cortex, synapse (human) RGD   Alzheimer Disease   ISS RGD:736378 7240710   OMIM   Alzheimer Disease Susceptibility ISS RGD:736378 6903233 DNA:missense mutations, haplotype:cds:p.C130R, p.C176R (human) RGD   Alzheimer Disease   IEA   1331525   RGD   Alzheimer Disease   IEP   6903910 protein:increased expression:hippocampus, synapse (rat) RGD   Alzheimer disease type 2   ISS RGD:736378 7240710   OMIM   Aortic Aneurysm, Abdominal   ISS RGD:736378 1578483 DNA:missense mutations, haplotypes:cds:p.C130R, p.C176R (human) RGD   Aortic Aneurysm, Abdominal   ISS RGD:733604 6903247   RGD   Atherosclerosis   ISS RGD:733604 734968   RGD   Bile Duct Neoplasms Susceptibility ISS RGD:736378 2317550 DNA:SNP:intron:rs440446 (human) RGD   Brain Injuries   IEA   1331525   RGD   Carcinoma, Hepatocellular   ISS RGD:733604 6903288 protein:increased expression:liver, serum (mouse) RGD   Cardiomyopathy, Dilated Susceptibility ISS RGD:736378 1601240   RGD   Cardiovascular Diseases   IEA   1331525   RGD   Carotid Artery Diseases   IEA   1331525   RGD   Cerebral Hemorrhage   ISS RGD:736378 6904207 DNA:missense mutations, haplotype:cds:p.C130R, p.C176R (human) RGD   Cerebral Infarction Susceptibility ISS RGD:736378 1601237 DNA:polymorphism: :3932T>C (human) RGD   Cerebrovascular Disorders Susceptibility ISS RGD:736378 1601227   RGD   Cholelithiasis Susceptibility ISS RGD:736378 2317550 DNA:SNP:intron:rs440446 (human) RGD   Cholestasis   ISS RGD:736378 2317548 associated with Pancreatic Neoplasms;protein:increased expression:plasma RGD   Coronary Artery Disease   ISS RGD:736378 1578449 DNA:missense mutations, haplotypes:cds:p.C130R, p.C176R (human) RGD   Coronary Artery Disease   ISS RGD:736378 1626412 associated with Diabetes Mellitus, Non-Insulin Dependent;DNA:SNP:promoter:-219G>T (human) RGD   Coronary Artery Disease   IEA   1331525   RGD   Coronary Disease   ISS RGD:736378 1578479 DNA:polymorphisms, haplotype:promoter, cds:g.-219G>T, p.C130R, p.C176R (human) RGD   Craniocerebral Trauma   ISS RGD:736378 7240710   OMIM   Dementia   IEA   1331525   RGD   Diabetes Mellitus, Experimental   IEP   1599198 protein:decreased expression:plasma (rat) RGD   Diabetes Mellitus, Type 1   IEA   1331525   RGD   Diabetes Mellitus, Type 1   ISS RGD:736378 6903197 protein:decreased expression:urine (human) RGD   Diabetes Mellitus, Type 2   ISS RGD:736378 2317556 protein:increased expression:pancreatic islet RGD   Diabetes Mellitus, Type 2   IEA   1331525   RGD   Diabetic Nephropathies   ISS RGD:733604 6902935 associated with Diabetes Mellitus, Experimental RGD   Diabetic Nephropathies Susceptibility ISS RGD:736378 6903840 DNA:missense mutations, haplotype:cds:p.C130R, p.C176R (human) RGD   Endotoxemia   ISS RGD:736378 6904216 rat model treated with human protein RGD   Gallbladder Neoplasms Susceptibility ISS RGD:736378 2317550 DNA:SNP:intron:rs440446 (human) RGD   Glaucoma   IEA   1331525   RGD   Glomerulonephritis   ISS RGD:733604 6903286 Apoe(-/-) Id3(-/-) double knockout RGD   Glomerulonephritis, Membranous   IEP   6903854 protein:increased expression:serum (rat) RGD   Glomerulosclerosis   IED   6903285   RGD   Glomerulosclerosis   IEP   6903199 protein:increased expression:renal glomerulus (rat) RGD   Hypercholesterolemia Resistance ISS RGD:736378 6903838 associated with Kidney Failure, Chronic; more ... RGD   Hypercholesterolemia Susceptibility ISS RGD:736378 1601229 DNA:missense mutations, haplotypes:cds:p.C130R, p.C176R (human) RGD   Hypercholesterolemia   ISS RGD:733604 734968   RGD   Hyperlipidemia, Familial Combined   ISS RGD:736378 1601231 DNA:missense mutations, haplotype:cds:p.C130R, p.C176R (human) RGD   Hyperlipidemia, Familial Combined   ISS RGD:736378 1578481 DNA:missense mutations, haplotype:cds:p.C130R, p.C176R (human) RGD   Hyperlipidemias   IED   6903856   RGD   Hyperlipidemias   IEA   1331525   RGD   Hyperlipoproteinemia Type III   IEA   1331525   RGD   Hyperlipoproteinemia Type III   ISS RGD:736378 7240710   OMIM   Hyperlipoproteinemias   ISS RGD:736378 7240710   OMIM   Hypertension   IEA   1331525   RGD   Hypertension Onset IEP   6904214 mRNA:decreased expression:multiple (rat) RGD   Hypertriglyceridemia Resistance ISS RGD:736378 1601235 associated with Metabolic Syndrome X; more ... RGD   Hypertriglyceridemia   ISS RGD:736378 7240710   OMIM   Hypertriglyceridemia   ISS RGD:733604 1601230   RGD   Hyperuricemia Resistance ISS RGD:736378 1601235 associated with Metabolic Syndrome X; more ... RGD   Infarction, Middle Cerebral Artery   IED   6903926   RGD   Kidney Failure, Chronic   ISS RGD:733604 6903287   RGD   Kidney Failure, Chronic   ISS RGD:736378 6904217 protein:increased expression:serum (human) RGD   Lipoprotein Glomerulopathy   ISS RGD:736378 6903201 human mutant gene (p.R145P) in mouse knockout RGD   Lipoprotein Glomerulopathy   ISS RGD:736378 7240710   OMIM   Lipoprotein Glomerulopathy   ISS RGD:736378 6903202 DNA:missense mutation:cds:p.R145P (human) RGD   Macular Degeneration   IEA   1331525   RGD   Macular Degeneration   ISS RGD:736378 7240710   OMIM   Macular Degeneration, Age-Related, 1   ISS RGD:736378 7240710   OMIM   Memory Disorders   ISS RGD:736378 1578426 DNA:missense mutations, haplotypes:cds:p.C130R, p.C176R (human) RGD   Multiple Sclerosis   IEA   1331525   RGD   Multiple Sclerosis   ISS RGD:736378 7240710   OMIM   Myocardial Infarction Susceptibility ISS RGD:736378 1601229 DNA:missense mutations, haplotypes:cds:p.C130R, p.C176R (human) RGD   Myocardial Infarction   ISS RGD:736378 7240710   OMIM   Myocardial Infarction   IEA   1331525   RGD   Myocardial Ischemia Susceptibility ISS RGD:736378 1601238 DNA:polymorphism:promoter:-219G>T (human) RGD   Non-alcoholic Fatty Liver Disease   IED   6904141   RGD   Obesity   ISS RGD:736378 1601191 protein:increased expression:serum RGD   Obesity   IEA   1331525   RGD   Pancreatic Neoplasms   IEP RGD:736378 2317552 protein:increased expression:pancreas RGD   Peripheral Nerve Injuries   IEP   6906875 protein:increased expression:sciatic nerve (rat) RGD   Peripheral Nerve Injuries   ISS RGD:736378 6906874 mouse model treated with human peptide RGD   Sea-Blue Histiocyte Syndrome   ISS RGD:736378 7240710   OMIM   Sleep Apnea Syndromes   IEA   1331525   RGD   Splenomegaly   ISS RGD:736378 7240710   OMIM   Stroke   IEA   1331525   RGD   Subarachnoid Hemorrhage   IEA   1331525   RGD   Vascular System Injuries   ISS RGD:733604 6904145   RGD   Vascular System Injuries   IEP   5509868 protein:decreased expression:plasma (rat) RGD   Venous Thrombosis   ISS RGD:733604 6903200   RGD   Gene-Chemical Interaction Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) (3S,5R)-fluvastatin multiple interactions ISO RGD:736378 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin CTD PMID:19773416 (3S,5R)-fluvastatin increases expression ISO RGD:736378 6480464 fluvastatin results in increased expression of APOE protein CTD PMID:8017468 (S)-nicotine increases expression ISO RGD:733604 6480464 Nicotine results in increased expression of APOE mRNA CTD PMID:17997037 11-dehydro-thromboxane B2 multiple interactions ISO RGD:736378 6480464 dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; more ... CTD PMID:20530721 17alpha-ethynylestradiol affects expression ISO RGD:733604 6480464 Ethinyl Estradiol affects the expression of APOE mRNA CTD PMID:17555576 17alpha-ethynylestradiol decreases expression ISO RGD:733604 6480464 Ethinyl Estradiol results in decreased expression of APOE mRNA CTD PMID:17942748 more ... 17alpha-ethynylestradiol decreases expression EXP   6480464 Ethinyl Estradiol results in decreased expression of APOE mRNA CTD PMID:17351261 PMID:17557909 17alpha-ethynylestradiol decreases expression ISO RGD:733604 6480464 Ethinyl Estradiol results in decreased expression of APOE mRNA CTD PMID:14976129 more ... 17alpha-ethynylestradiol decreases expression EXP   6480464 Ethinyl Estradiol results in decreased expression of APOE mRNA CTD PMID:17557909 PMID:17351261 17alpha-ethynylestradiol increases expression EXP   6480464 Ethinyl Estradiol results in increased expression of APOE mRNA CTD PMID:16174780 17alpha-ethynylestradiol multiple interactions ISO RGD:733604 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of APOE mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression ISO RGD:733604 6480464 Ethinyl Estradiol results in decreased expression of APOE mRNA CTD PMID:16174780 more ... 17beta-hydroxy-5alpha-androstan-3-one multiple interactions ISO RGD:736378 6480464 APOE gene polymorphism affects the reaction [Dihydrotestosterone affects the phosphorylation of MAPK9 protein]; more ... CTD PMID:17395708 17beta-hydroxy-5alpha-androstan-3-one affects response to substance ISO RGD:736378 6480464 APOE gene polymorphism affects the susceptibility to Dihydrotestosterone CTD PMID:17395708 2,2',5,5'-tetrachlorobiphenyl affects expression ISO RGD:736378 6480464 2,5,2',5'-tetrachlorobiphenyl affects the expression of APOE mRNA CTD PMID:21703328 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:733604 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of APOE mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Tetrachlorodibenzodioxin CTD PMID:12213967 PMID:21441140 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:736378 6480464 Tetrachlorodibenzodioxin results in increased expression of APOE mRNA CTD PMID:20106945 PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:733604 6480464 Tetrachlorodibenzodioxin affects the expression of APOE mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:733604 6480464 Tetrachlorodibenzodioxin results in increased expression of APOE mRNA CTD PMID:21041162 2,3,7,8-tetrachlorodibenzodioxine affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Tetrachlorodibenzodioxin CTD PMID:12213967 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:736378 6480464 Tetrachlorodibenzodioxin results in increased expression of APOE mRNA CTD PMID:20106945 2-amino-2-deoxy-D-glucopyranose multiple interactions ISO RGD:733604 6480464 INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] CTD PMID:16380481 2-butoxyethanol decreases expression ISO RGD:733604 6480464 n-butoxyethanol results in decreased expression of APOE mRNA CTD PMID:19812364 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine decreases response to substance ISO RGD:733604 6480464 APOE protein results in decreased susceptibility to Puromycin Aminonucleoside CTD PMID:12472773 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine increases expression EXP   6480464 Puromycin Aminonucleoside results in increased expression of APOE protein CTD PMID:7442475 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine affects expression EXP   6480464 Puromycin Aminonucleoside affects the expression of APOE mRNA CTD PMID:8413767 3H-1,2-dithiole-3-thione increases expression EXP   6480464 1,2-dithiol-3-thione results in increased expression of APOE mRNA CTD PMID:19162173 6-oxo-prostaglandin F1alpha increases abundance ISO RGD:733604 6480464 APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha CTD PMID:14966570 6-oxo-prostaglandin F1alpha multiple interactions ISO RGD:733604 6480464 nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha] CTD PMID:14966570 7,12-dimethyltetraphene affects expression ISO RGD:733604 6480464 9,10-Dimethyl-1,2-benzanthracene affects the expression of APOE mRNA CTD PMID:21785161 8-epi-prostaglandin F2alpha multiple interactions ISO RGD:733604 6480464 [APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha CTD PMID:17118406 acenocoumarol affects response to substance ISO RGD:736378 6480464 APOE gene polymorphism affects the susceptibility to Acenocoumarol CTD PMID:15861030 acetylcholine affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Acetylcholine CTD PMID:17899169 acetylsalicylic acid affects response to substance ISO RGD:736378 6480464 APOE polymorphism affects the susceptibility to Aspirin CTD PMID:15084783 acetylsalicylic acid multiple interactions ISO RGD:733604 6480464 Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] CTD PMID:20530721 acetylsalicylic acid multiple interactions ISO RGD:736378 6480464 Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] CTD PMID:20530721 acrolein affects folding ISO RGD:736378 6480464 Acrolein affects the folding of APOE protein CTD PMID:17580963 acrolein decreases activity ISO RGD:736378 6480464 Acrolein results in decreased activity of APOE protein CTD PMID:17580963 aflatoxin B1 affects expression ISO RGD:736378 6480464 Aflatoxin B1 affects the expression of APOE protein CTD PMID:20106945 aflatoxin B1 decreases expression ISO RGD:733604 6480464 Aflatoxin B1 results in decreased expression of APOE mRNA CTD PMID:19770486 aldehydo-D-glucosamine multiple interactions ISO RGD:733604 6480464 INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] CTD PMID:16380481 all-trans-retinoic acid multiple interactions ISO RGD:733604 6480464 AGN 193109 inhibits the reaction [Tretinoin results in increased expression of APOE mRNA] CTD PMID:16505366 all-trans-retinoic acid increases expression ISO RGD:733604 6480464 Tretinoin results in increased expression of APOE mRNA CTD PMID:16505366 amiodarone decreases expression EXP   6480464 Amiodarone results in decreased expression of APOE mRNA CTD PMID:17991464 ammonium chloride affects expression EXP   6480464 Ammonium Chloride affects the expression of APOE mRNA CTD PMID:16483693 arachidonic acid multiple interactions ISO RGD:736378 6480464 APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; more ... CTD PMID:20530721 arachidonic acid multiple interactions ISO RGD:733604 6480464 Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; more ... CTD PMID:20530721 arachidonic acid decreases response to substance ISO RGD:733604 6480464 APOE gene mutant form results in decreased susceptibility to Arachidonic Acid CTD PMID:20530721 arsenic atom increases response to substance ISO RGD:736378 6480464 APOE polymorphism results in increased susceptibility to Arsenic CTD PMID:18022660 arsenic atom increases response to substance ISO RGD:733604 6480464 APOE gene mutant form results in increased susceptibility to Arsenic CTD PMID:22956628 arsenic atom affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Arsenic CTD PMID:22719926 arsenic atom multiple interactions ISO RGD:733604 6480464 [APOE protein affects the susceptibility to Arsenic] which affects the expression of AQP1 mRNA; more ... CTD PMID:22719926 benzo[a]pyrene decreases expression ISO RGD:733604 6480464 Benzo(a)pyrene results in decreased expression of APOE mRNA CTD PMID:19770486 beta-D-glucosamine multiple interactions ISO RGD:733604 6480464 INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] CTD PMID:16380481 bezafibrate multiple interactions ISO RGD:736378 6480464 [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with atorvastatin co-treated with valsartan] results in decreased expression of APOE protein CTD PMID:19603250 bezafibrate increases expression ISO RGD:736378 6480464 Bezafibrate results in increased expression of APOE protein CTD PMID:8017468 bezafibrate decreases expression EXP   6480464 Bezafibrate results in decreased expression of APOE protein CTD PMID:9006809 bezafibrate multiple interactions EXP   6480464 [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein CTD PMID:8944747 calcium atom affects abundance ISO RGD:733604 6480464 APOE protein affects the abundance of Calcium CTD PMID:17899169 calcium atom affects expression EXP   6480464 Calcium affects the expression of APOE mRNA CTD PMID:15913539 calcium(0) affects abundance ISO RGD:733604 6480464 APOE protein affects the abundance of Calcium CTD PMID:17899169 calcium(0) affects expression EXP   6480464 Calcium affects the expression of APOE mRNA CTD PMID:15913539 capsaicin multiple interactions ISO RGD:733604 6480464 Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; more ... CTD PMID:21908651 cetrorelix multiple interactions ISO RGD:736378 6480464 [cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA; more ... CTD PMID:18160741 chloroquine affects localization EXP   6480464 Chloroquine affects the localization of APOE protein CTD PMID:8616629 cholesterol affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Cholesterol CTD PMID:16179587 cholesterol increases export ISO RGD:733604 6480464 APOE protein results in increased export of Cholesterol CTD PMID:22022523 cholesterol multiple interactions ISO RGD:733604 6480464 [APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol; more ... CTD PMID:21908651 cholesterol multiple interactions ISO RGD:733604 6480464 APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol] CTD PMID:12472773 cisplatin increases expression ISO RGD:733604 6480464 Cisplatin results in increased expression of APOE mRNA CTD PMID:21151649 cisplatin decreases response to substance ISO RGD:736378 6480464 APOE protein results in decreased susceptibility to Cisplatin CTD PMID:20430468 clofibric acid multiple interactions EXP   6480464 [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein CTD PMID:8944747 cobalt atom multiple interactions ISO RGD:736378 6480464 [tungsten carbide co-treated with Cobalt] results in decreased expression of APOE mRNA CTD PMID:18078969 copper atom increases expression EXP   6480464 Copper deficiency results in increased expression of APOE mRNA CTD PMID:19821111 copper atom decreases expression EXP   6480464 Copper results in decreased expression of APOE mRNA CTD PMID:22465980 copper(0) increases expression EXP   6480464 Copper deficiency results in increased expression of APOE mRNA CTD PMID:19821111 copper(0) decreases expression EXP   6480464 Copper results in decreased expression of APOE mRNA CTD PMID:22465980 copper(2+) sulfate decreases expression ISO RGD:733604 6480464 Copper Sulfate results in decreased expression of APOE mRNA CTD PMID:18579281 cyclophosphamide decreases expression ISO RGD:733604 6480464 Cyclophosphamide results in decreased expression of APOE mRNA CTD PMID:15331540 cyclophosphamide increases expression ISO RGD:733604 6480464 Cyclophosphamide results in increased expression of APOE mRNA CTD PMID:21041162 cyclosporin A decreases expression ISO RGD:736378 6480464 Cyclosporine results in decreased expression of APOE mRNA CTD PMID:20106945 cypermethrin decreases expression EXP   6480464 cypermethrin results in decreased expression of APOE mRNA CTD PMID:11428908 PMID:9650644 cypermethrin increases expression ISO RGD:733604 6480464 cypermethrin results in increased expression of APOE mRNA CTD PMID:21142847 cypermethrin decreases expression EXP   6480464 cypermethrin results in decreased expression of APOE mRNA CTD PMID:9650644 PMID:11428908 desogestrel multiple interactions ISO RGD:736378 6480464 [cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA CTD PMID:18160741 dexamethasone increases expression ISO RGD:733604 6480464 Dexamethasone results in increased expression of APOE mRNA CTD PMID:21041162 diarsenic trioxide decreases expression ISO RGD:736378 6480464 arsenic trioxide results in decreased expression of APOE mRNA CTD PMID:22521957 diethylstilbestrol increases expression ISO RGD:736378 6480464 Diethylstilbestrol results in increased expression of APOE mRNA CTD PMID:15766595 diethylstilbestrol increases expression ISO RGD:733604 6480464 Diethylstilbestrol results in increased expression of APOE mRNA CTD PMID:21041162 diethylstilbestrol decreases expression ISO RGD:733604 6480464 Diethylstilbestrol results in decreased expression of APOE mRNA CTD PMID:15171707 dipyridamole multiple interactions ISO RGD:736378 6480464 [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with atorvastatin co-treated with valsartan] results in decreased expression of APOE protein CTD PMID:19603250 diuron decreases expression EXP   6480464 Diuron results in decreased expression of APOE mRNA CTD PMID:21551480 doxorubicin increases expression ISO RGD:733604 6480464 Doxorubicin results in increased expression of APOE mRNA CTD PMID:15033991 doxorubicin increases expression EXP   6480464 Doxorubicin results in increased expression of APOE protein CTD PMID:8255516 elemental selenium increases expression ISO RGD:736378 6480464 Selenium results in increased expression of APOE mRNA CTD PMID:19244175 elemental selenium affects expression ISO RGD:733604 6480464 Selenium affects the expression of APOE protein CTD PMID:17996733 enalapril multiple interactions ISO RGD:736378 6480464 [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with atorvastatin co-treated with valsartan] results in decreased expression of APOE protein CTD PMID:19603250 ethanolamine multiple interactions EXP   6480464 [3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein; more ... CTD PMID:8944747 felodipine multiple interactions ISO RGD:733604 6480464 Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of NFKB1 protein]; more ... CTD PMID:18287887 flutamide increases expression EXP   6480464 Flutamide results in increased expression of APOE protein CTD PMID:17311803 folic acid affects response to substance ISO RGD:733604 6480464 APOE gene mutant form affects the susceptibility to Folic Acid CTD PMID:17118406 folic acid multiple interactions ISO RGD:733604 6480464 [APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha; more ... CTD PMID:17118406 gemfibrozil increases expression EXP   6480464 Gemfibrozil results in increased expression of APOE protein CTD PMID:9006809 genistein decreases expression ISO RGD:733604 6480464 Genistein results in decreased expression of APOE mRNA CTD PMID:21048042 hydrazine decreases expression EXP   6480464 hydrazine results in decreased expression of APOE mRNA; more ... CTD PMID:15370871 hydrogen peroxide affects localization EXP   6480464 Hydrogen Peroxide affects the localization of APOE protein CTD PMID:19720132 hydrogen peroxide increases expression EXP   6480464 Hydrogen Peroxide results in increased expression of APOE mRNA CTD PMID:19720132 indomethacin multiple interactions ISO RGD:733604 6480464 Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] CTD PMID:20530721 iron atom increases response to substance ISO RGD:736378 6480464 APOE gene polymorphism results in increased susceptibility to Iron CTD PMID:15993987 isotretinoin affects response to substance ISO RGD:736378 6480464 APOE gene polymorphism affects the susceptibility to Isotretinoin CTD PMID:12622636 kaempferol multiple interactions ISO RGD:733604 6480464 kaempferol inhibits the reaction [APOE affects the expression of CD44 protein]; more ... CTD PMID:22005275 kainic acid decreases expression ISO RGD:733604 6480464 Kainic Acid results in decreased expression of APOE mRNA CTD PMID:17997037 ketamine decreases response to substance ISO RGD:736378 6480464 APOE results in decreased susceptibility to Ketamine CTD PMID:9778666 ketamine increases expression EXP   6480464 Ketamine results in increased expression of APOE mRNA CTD PMID:20080153 L-ascorbic acid increases expression EXP   6480464 Ascorbic Acid results in increased expression of APOE mRNA CTD PMID:15372504 lansoprazole increases expression ISO RGD:736378 6480464 lansoprazole results in increased expression of APOE mRNA; more ... CTD PMID:20060385 lansoprazole increases expression ISO RGD:733604 6480464 lansoprazole results in increased expression of APOE protein CTD PMID:20060385 lead diacetate increases expression ISO RGD:733604 6480464 lead acetate results in increased expression of APOE mRNA CTD PMID:21829687 lead(0) affects expression ISO RGD:736378 6480464 Lead affects the expression of APOE protein CTD PMID:20681587 mercury atom affects response to substance ISO RGD:736378 6480464 APOE polymorphism affects the susceptibility to Mercury CTD PMID:12897404 mercury(0) affects response to substance ISO RGD:736378 6480464 APOE polymorphism affects the susceptibility to Mercury CTD PMID:12897404 mono(2-ethylhexyl) phthalate increases expression EXP   6480464 mono-(2-ethylhexyl)phthalate results in increased expression of APOE mRNA CTD PMID:22087261 morphine increases expression EXP   6480464 Morphine results in increased expression of APOE protein CTD PMID:23056601 morphine multiple interactions EXP   6480464 Morphine deficiency affects the reaction [Morphine results in increased expression of APOE protein] CTD PMID:23056601 N-nitrosodiethylamine multiple interactions EXP   6480464 [Phenobarbital co-treated with Diethylnitrosamine] results in increased expression of APOE protein CTD PMID:20935162 N-tosyl-L-phenylalanyl chloromethyl ketone multiple interactions ISO RGD:736378 6480464 Tosylphenylalanyl Chloromethyl Ketone promotes the reaction [APOA1 protein results in increased expression of APOE mRNA]; more ... CTD PMID:22056562 nickel sulfate decreases expression ISO RGD:736378 6480464 nickel sulfate results in decreased expression of APOE mRNA CTD PMID:16780908 nickel sulfate increases expression ISO RGD:736378 6480464 nickel sulfate results in increased expression of APOE mRNA CTD PMID:16780908 nimesulide multiple interactions ISO RGD:733604 6480464 nimesulide inhibits the reaction [APOE results in decreased expression of CCNA2 protein]; more ... CTD PMID:14966570 ochratoxin A increases expression EXP   6480464 ochratoxin A results in increased expression of APOE mRNA CTD PMID:23358140 ozone decreases expression ISO RGD:733604 6480464 Ozone results in decreased expression of APOE mRNA CTD PMID:12763052 paracetamol decreases expression EXP   6480464 Acetaminophen results in decreased expression of APOE protein CTD PMID:16687475 paracetamol increases expression ISO RGD:733604 6480464 Acetaminophen results in increased expression of APOE mRNA CTD PMID:23358195 paracetamol affects expression EXP   6480464 Acetaminophen affects the expression of APOE protein CTD PMID:16099942 paricalcitol multiple interactions ISO RGD:736378 6480464 [Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA CTD PMID:17715259 perfluorooctanoic acid increases expression ISO RGD:736378 6480464 perfluorooctanoic acid results in increased expression of APOE protein CTD PMID:22609092 phenobarbital affects expression EXP   6480464 Phenobarbital affects the expression of APOE protein CTD PMID:16099942 phenobarbital multiple interactions EXP   6480464 [Phenobarbital co-treated with Diethylnitrosamine] results in increased expression of APOE protein CTD PMID:20935162 phenylephrine affects response to substance ISO RGD:733604 6480464 APOE protein affects the susceptibility to Phenylephrine CTD PMID:17899169 phenytoin increases expression ISO RGD:733604 6480464 Phenytoin results in increased expression of APOE mRNA CTD PMID:15136057 phosphorus atom multiple interactions ISO RGD:736378 6480464 [Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA CTD PMID:17715259 phosphorus(.) multiple interactions ISO RGD:736378 6480464 [Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA CTD PMID:17715259 pirinixic acid affects expression EXP   6480464 pirinixic acid affects the expression of APOE protein CTD PMID:16099942 quercetin increases expression ISO RGD:733604 6480464 Quercetin results in increased expression of APOE mRNA CTD PMID:16455785 quercetin increases expression ISO RGD:736378 6480464 Quercetin results in increased expression of APOE mRNA CTD PMID:21632981 rel-(3R,5S)-fluvastatin multiple interactions ISO RGD:736378 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin CTD PMID:19773416 rel-(3R,5S)-fluvastatin increases expression ISO RGD:736378 6480464 fluvastatin results in increased expression of APOE protein CTD PMID:8017468 resveratrol increases expression ISO RGD:733604 6480464 resveratrol results in increased expression of APOE mRNA CTD PMID:22610192 resveratrol decreases expression EXP   6480464 resveratrol results in decreased expression of APOE mRNA CTD PMID:19228061 resveratrol increases expression ISO RGD:736378 6480464 resveratrol results in increased expression of APOE mRNA CTD PMID:19371625 retinyl acetate increases expression ISO RGD:733604 6480464 retinol acetate results in increased expression of APOE mRNA CTD PMID:16772331 rosiglitazone affects response to substance ISO RGD:736378 6480464 APOE gene polymorphism affects the susceptibility to rosiglitazone CTD PMID:16446752 rosiglitazone increases expression ISO RGD:736378 6480464 rosiglitazone results in increased expression of APOE mRNA; more ... CTD PMID:16386711 selenium atom increases expression ISO RGD:736378 6480464 Selenium results in increased expression of APOE mRNA CTD PMID:19244175 selenium atom affects expression ISO RGD:733604 6480464 Selenium affects the expression of APOE protein CTD PMID:17996733 simvastatin affects response to substance ISO RGD:736378 6480464 APOE polymorphism affects the susceptibility to Simvastatin CTD PMID:12901521 PMID:11849659 simvastatin decreases expression EXP   6480464 Simvastatin results in decreased expression of APOE mRNA CTD PMID:8461338 PMID:8289597 simvastatin affects response to substance ISO RGD:736378 6480464 APOE polymorphism affects the susceptibility to Simvastatin CTD PMID:11849659 PMID:12901521 simvastatin multiple interactions EXP   6480464 Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein] CTD PMID:8461338 simvastatin decreases expression EXP   6480464 Simvastatin results in decreased expression of APOE protein CTD PMID:8461338 simvastatin decreases expression EXP   6480464 Simvastatin results in decreased expression of APOE mRNA CTD PMID:8289597 PMID:8461338 simvastatin affects response to substance ISO RGD:733604 6480464 APOE affects the susceptibility to Simvastatin CTD PMID:11947894 simvastatin decreases expression ISO RGD:736378 6480464 Simvastatin results in decreased expression of APOE mRNA CTD PMID:18270459 simvastatin decreases expression ISO RGD:736378 6480464 Simvastatin results in decreased expression of APOE CTD PMID:19461118 sodium dichromate increases expression EXP   6480464 sodium bichromate results in increased expression of APOE mRNA CTD PMID:22561333 streptozocin increases expression EXP   6480464 Streptozocin results in increased expression of APOE mRNA CTD PMID:16684804 streptozocin multiple interactions ISO RGD:733604 6480464 INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] CTD PMID:16380481 streptozocin multiple interactions EXP   6480464 vanadyl sulfate inhibits the reaction [Streptozocin results in increased expression of APOE mRNA] CTD PMID:16684804 superoxide increases chemical synthesis ISO RGD:733604 6480464 APOE gene mutant form results in increased chemical synthesis of Superoxides CTD PMID:12871831 superoxide multiple interactions ISO RGD:733604 6480464 M 40403 inhibits the reaction [APOE gene mutant form results in increased chemical synthesis of Superoxides]; more ... CTD PMID:12871831 tamoxifen affects response to substance ISO RGD:736378 6480464 APOE gene polymorphism affects the susceptibility to Tamoxifen CTD PMID:19103187 tamoxifen affects expression ISO RGD:733604 6480464 Tamoxifen affects the expression of APOE mRNA CTD PMID:17555576 tert-butyl hydroperoxide increases expression ISO RGD:736378 6480464 tert-Butylhydroperoxide results in increased expression of APOE mRNA CTD PMID:15336504 tert-butyl hydroperoxide affects localization EXP   6480464 tert-Butylhydroperoxide affects the localization of APOE protein CTD PMID:19720132 tert-butyl hydroperoxide increases expression EXP   6480464 tert-Butylhydroperoxide results in increased expression of APOE mRNA CTD PMID:19720132 testosterone enanthate multiple interactions ISO RGD:736378 6480464 [cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA; more ... CTD PMID:18160741 tetrachloromethane increases expression EXP   6480464 Carbon Tetrachloride results in increased expression of APOE protein CTD PMID:16845489 trans-resveratrol increases expression ISO RGD:733604 6480464 resveratrol results in increased expression of APOE mRNA CTD PMID:22610192 trans-resveratrol decreases expression EXP   6480464 resveratrol results in decreased expression of APOE mRNA CTD PMID:19228061 trans-resveratrol increases expression ISO RGD:736378 6480464 resveratrol results in increased expression of APOE mRNA CTD PMID:19371625 trimellitic anhydride decreases expression ISO RGD:733604 6480464 trimellitic anhydride results in decreased expression of APOE mRNA CTD PMID:19042947 troglitazone increases expression ISO RGD:736378 6480464 troglitazone results in increased expression of APOE mRNA CTD PMID:19140230 valsartan multiple interactions ISO RGD:736378 6480464 [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with atorvastatin co-treated with valsartan] results in decreased expression of APOE protein CTD PMID:19603250 valsartan multiple interactions ISO RGD:736378 6480464 valsartan inhibits the reaction [AGT protein results in decreased expression of APOE protein] CTD PMID:17785354 vanadyl sulfate multiple interactions EXP   6480464 vanadyl sulfate inhibits the reaction [Streptozocin results in increased expression of APOE mRNA] CTD PMID:16684804 vitamin K affects abundance ISO RGD:736378 6480464 APOE protein affects the abundance of Vitamin K CTD PMID:15952022 vitamin K affects uptake ISO RGD:736378 6480464 APOE protein affects the uptake of Vitamin K CTD PMID:16847429 zearalenone decreases expression ISO RGD:736378 6480464 Zearalenone results in decreased expression of APOE mRNA CTD PMID:19371625 Gene Ontology Annotations Biological Process Term Qualifier Evidence With Reference Notes Source Original Reference(s) aging   IDA   2317724   RGD   artery morphogenesis   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:3695082 PMID:16230502 artery morphogenesis   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 axon regeneration NOT ISO RGD:733604 1624291 MGI:MGI:88049 RGD MGI:MGI:70238 PMID:7798939 cardiovascular system development   ISO RGD:733604 1624291 MGI:MGI:4443305|PMID:19816508 RGD MGI:MGI:4443305 PMID:19816508 cellular calcium ion homeostasis   ISO RGD:733604 1624291 MGI:MGI:66090|PMID:8185566 RGD MGI:MGI:66090 PMID:8185566 cellular calcium ion homeostasis   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 cellular response to cholesterol   IEP   6904144   RGD   cellular response to growth factor stimulus   IEP   2317725   RGD   cellular response to growth factor stimulus   IEP   6904215 brain derived neurotrophic factor RGD   cellular response to interleukin-1   IEP   6903907   RGD   cGMP-mediated signaling   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 cGMP-mediated signaling   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 cholesterol catabolic process   ISO RGD:733604 1624291 MGI:MGI:1314982|PMID:9826706 RGD MGI:MGI:1314982 PMID:9826706 cholesterol catabolic process   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 cholesterol efflux   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:2151732 PMID:11551841 cholesterol efflux   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 cholesterol efflux   ISO RGD:736378 1624291 PMID:16443932 RGD PMID:16443932 cholesterol efflux   ISO RGD:736378 1624291 PMID:11162594 RGD PMID:11162594 cholesterol efflux   ISO RGD:733604 1624291 MGI:MGI:3056863|PMID:15269218 RGD MGI:MGI:3056863 PMID:15269218 cholesterol homeostasis   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:51330 PMID:1423598 cholesterol homeostasis   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 cholesterol homeostasis   ISO RGD:736378 1624291 PMID:9649566 RGD PMID:9649566 cholesterol homeostasis   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:3695082 PMID:16230502 cholesterol homeostasis   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:1928445 PMID:11120757 cholesterol homeostasis   ISO RGD:733604 1624291 MGI:MGI:1857129 RGD MGI:MGI:70238 PMID:7798939 cholesterol metabolic process   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:51330 PMID:1423598 cholesterol metabolic process   ISO RGD:736378 1624291 PMID:9649566 RGD PMID:9649566 cholesterol metabolic process   ISO RGD:736378 1624291 PMID:3771793 RGD PMID:3771793 cholesterol metabolic process   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:2180727 PMID:8647961 chylomicron remnant clearance   ISO RGD:736378 1624291 PMID:7175379 RGD PMID:7175379 chylomicron remnant clearance   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 G-protein coupled receptor signaling pathway   ISO RGD:736378 1624291 PMID:16443932 RGD PMID:16443932 G-protein coupled receptor signaling pathway   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 high-density lipoprotein particle assembly   ISO RGD:736378 1624291 PMID:17305370 RGD PMID:17305370 high-density lipoprotein particle assembly   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 high-density lipoprotein particle clearance   ISO RGD:736378 1624291 PMID:210175 RGD PMID:210175 high-density lipoprotein particle clearance   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 high-density lipoprotein particle remodeling   ISO RGD:736378 1624291 UniProtKB:P08226 RGD PMID:12401887 high-density lipoprotein particle remodeling   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 induction of apoptosis   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 lipid homeostasis   ISO RGD:733604 1624291 MGI:MGI:1857303 RGD MGI:MGI:3770508 PMID:17720994 lipid metabolic process   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:1928445 PMID:11120757 lipid transport   IDA   1626397   RGD   lipid transport   IDA   634663   RGD   lipoprotein biosynthetic process   ISO RGD:733604 1624291 MGI:MGI:88049 RGD MGI:MGI:3709144 PMID:14595002 lipoprotein biosynthetic process   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 lipoprotein catabolic process   ISO RGD:733604 1624291 MGI:MGI:1857303 RGD MGI:MGI:3770508 PMID:17720994 lipoprotein catabolic process   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 lipoprotein metabolic process   IDA   1626397   RGD   lipoprotein metabolic process   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:3028770 PMID:13130124 lipoprotein metabolic process   ISO RGD:733604 1624291 MGI:MGI:88052 RGD MGI:MGI:1928445 PMID:11120757 lipoprotein metabolic process   ISO RGD:733604 1624291 MGI:MGI:1857129 RGD MGI:MGI:1313233 PMID:9788969 low-density lipoprotein particle remodeling   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 low-density lipoprotein particle remodeling   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 maintenance of location in cell   ISO RGD:733604 1624291 MGI:MGI:1857303 RGD MGI:MGI:3770508 PMID:17720994 maintenance of location in cell   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of apoptotic process   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 negative regulation of blood coagulation   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 negative regulation of blood vessel endothelial cell migration   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 negative regulation of blood vessel endothelial cell migration   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of cholesterol biosynthetic process   ISO RGD:736378 1624291 PMID:1917954 RGD PMID:1917954 negative regulation of cholesterol biosynthetic process   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of endothelial cell proliferation   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 negative regulation of endothelial cell proliferation   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of inflammatory response   ISO RGD:733604 1624291 UniProtKB:P22893 RGD MGI:MGI:5301204 PMID:21784977 negative regulation of inflammatory response   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of MAP kinase activity   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 negative regulation of MAP kinase activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 negative regulation of neuron apoptotic process   IDA   1625020 retinal ganglion cells RGD   negative regulation of platelet activation   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 negative regulation of platelet activation   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 neuron projection regeneration   TAS   1358286   RGD   nitric oxide mediated signal transduction   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 nitric oxide mediated signal transduction   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 oligodendrocyte differentiation   IEP   6903911   RGD   peripheral nervous system axon regeneration   IEP   2311210   RGD   phospholipid efflux   ISO RGD:736378 1624291 PMID:11162594 RGD PMID:11162594 phospholipid efflux   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of axon extension   IDA   6904146   RGD   positive regulation of catalytic activity   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 positive regulation of cGMP biosynthetic process   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 positive regulation of cGMP biosynthetic process   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of cholesterol efflux   ISO RGD:736378 1624291 UniProtKB:P08226 RGD PMID:12401887 positive regulation of cholesterol efflux   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of cholesterol efflux   ISO RGD:736378 1624291 PMID:14754908 RGD PMID:14754908 positive regulation of cholesterol esterification   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 positive regulation of cholesterol esterification   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of cholesterol esterification   ISO RGD:736378 1624291 PMID:15654758 RGD PMID:15654758 positive regulation of low-density lipoprotein particle receptor catabolic process   ISO RGD:736378 1624291 PMID:15950758 RGD PMID:15950758 positive regulation of low-density lipoprotein particle receptor catabolic process   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of membrane protein ectodomain proteolysis   ISO RGD:736378 1624291 PMID:15950758 RGD PMID:15950758 positive regulation of membrane protein ectodomain proteolysis   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of nitric-oxide synthase activity   ISO RGD:736378 1624291 PMID:8995232 RGD PMID:8995232 positive regulation of nitric-oxide synthase activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 protein localization NOT ISO RGD:733604 1624291 MGI:MGI:1857129 RGD MGI:MGI:1097296 PMID:9325076 receptor-mediated endocytosis   ISO RGD:736378 1624291 PMID:1917954 RGD PMID:1917954 receptor-mediated endocytosis   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 regulation of Cdc42 protein signal transduction   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 regulation of Cdc42 protein signal transduction   ISO RGD:736378 1624291 PMID:16443932 RGD PMID:16443932 regulation of gene expression   ISO RGD:733604 1624291 MGI:MGI:1857303 RGD MGI:MGI:3770508 PMID:17720994 regulation of gene expression   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 response to dietary excess   ISO RGD:733604 1624291 MGI:MGI:1857303 RGD MGI:MGI:3770508 PMID:17720994 response to dietary excess   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 response to ethanol   IEP   1599196   RGD   response to insulin stimulus   IEP   6903858   RGD   response to oxidative stress   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:80909 PMID:8773783 response to oxidative stress   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 response to retinoic acid   IEP   6903285   RGD   reverse cholesterol transport   ISO RGD:736378 1624291 PMID:8127890 RGD PMID:8127890 reverse cholesterol transport   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 triglyceride metabolic process   ISO RGD:736378 1624291 PMID:3771793 RGD PMID:3771793 triglyceride metabolic process   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 triglyceride metabolic process   ISO RGD:736378 1624291 PMID:9649566 RGD PMID:9649566 vasodilation   ISO RGD:733604 1624291 MGI:MGI:2137814 RGD MGI:MGI:1314982 PMID:9826706 vasodilation   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle clearance   ISO RGD:736378 1624291 PMID:1917954 RGD PMID:1917954 very-low-density lipoprotein particle clearance   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle clearance   ISO RGD:736378 1624291 PMID:9649566 RGD PMID:9649566 very-low-density lipoprotein particle remodeling   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 very-low-density lipoprotein particle remodeling   ISO RGD:736378 1624291 UniProtKB:P08226 RGD PMID:12401887 very-low-density lipoprotein particle remodeling   ISO RGD:736378 1624291 PMID:15654758 RGD PMID:15654758 very-low-density lipoprotein particle remodeling   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 Cellular Component Term Qualifier Evidence With Reference Notes Source Original Reference(s) chylomicron   ISO RGD:736378 1624291 PMID:16935699 RGD PMID:16935699 chylomicron   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 chylomicron   ISO RGD:736378 1624291 PMID:8245722 RGD PMID:8245722 cytoplasm   IDA   1626380   RGD   cytoplasm   IDA   1599197   RGD   dendrite   IDA   1626380   RGD   early endosome Colocalizes_with IDA   2317724   RGD   extracellular space   ISO RGD:733604 1624291 MGI:MGI:892202|PMID:9186920 RGD MGI:MGI:892202 PMID:9186920 extracellular space   ISO RGD:736378 1624291 PMID:20551380 RGD PMID:20551380 extracellular space   IDA   1599198   RGD   extracellular space   ISO RGD:733604 1624291 MGI:MGI:70238|PMID:7798939 RGD MGI:MGI:70238 PMID:7798939 extracellular space   ISO RGD:733604 1624291 MGI:MGI:3056863|PMID:15269218 RGD MGI:MGI:3056863 PMID:15269218 extracellular space   ISO RGD:733604 1624291 MGI:MGI:1096057|PMID:9300780 RGD MGI:MGI:1096057 PMID:9300780 extrinsic to external side of plasma membrane   IDA   1599197   RGD   Golgi apparatus   IDA   1626382   RGD   Golgi apparatus   IDA   1599196   RGD   high-density lipoprotein particle   ISO RGD:736378 1624291 PMID:210174 RGD PMID:210174 high-density lipoprotein particle   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 intermediate-density lipoprotein particle   ISO RGD:736378 1624291 PMID:17336988 RGD PMID:17336988 intermediate-density lipoprotein particle   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 late endosome   IDA   1626382   RGD   low-density lipoprotein particle   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 low-density lipoprotein particle   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 low-density lipoprotein particle   ISO RGD:736378 1624291 PMID:8245722 RGD PMID:8245722 microtubule Colocalizes_with IDA   2317724   RGD   neuronal cell body   IDA   1626380   RGD   plasma membrane   IDA   6904144   RGD   very-low-density lipoprotein particle   ISO RGD:736378 1624291 PMID:17154273 RGD PMID:17154273 very-low-density lipoprotein particle   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle   ISO RGD:736378 1624291 PMID:8245722 RGD PMID:8245722 Molecular Function Term Qualifier Evidence With Reference Notes Source Original Reference(s) antioxidant activity   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 antioxidant activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 beta-amyloid binding   IDA   6903908   RGD   beta-amyloid binding   ISS UniProtKB:P02649 1600115 GO_REF:0000024 UniProtKB GO_REF:0000024 beta-amyloid binding   ISO RGD:736378 1624291 PMID:11305869 RGD PMID:11305869 cholesterol transporter activity   ISO RGD:733604 1624291 MGI:MGI:3056863|PMID:15269218 RGD MGI:MGI:3056863 PMID:15269218 cholesterol transporter activity   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 heparin binding   ISO RGD:736378 1624291 PMID:2745454 RGD PMID:2745454 heparin binding   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 hydroxyapatite binding   IDA   6903929   RGD   identical protein binding   ISO RGD:736378 1624291 PMID:4066713 RGD PMID:4066713 lipid binding   ISO RGD:736378 1624291 PMID:4066713 RGD PMID:4066713 lipid transporter activity   IDA   1626397   RGD   lipid transporter activity   ISO RGD:736378 1624291 PMID:17305370 RGD PMID:17305370 lipid transporter activity   IDA   634663   RGD   lipoprotein particle binding   ISO RGD:733604 1624291 MGI:MGI:2150868|PMID:11553788 RGD MGI:MGI:2150868 PMID:11553788 lipoprotein particle binding   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 low-density lipoprotein particle receptor binding   ISO RGD:736378 1624291 UniProtKB:Q92673 RGD PMID:17326667 low-density lipoprotein particle receptor binding   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 low-density lipoprotein particle receptor binding   ISO RGD:736378 1624291 PMID:210175 RGD PMID:210175 metal chelating activity   ISO RGD:736378 1624291 PMID:9685360 RGD PMID:9685360 metal chelating activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 phosphatidylcholine-sterol O-acyltransferase activator activity   ISO RGD:733604 1624291 MGI:MGI:3850619|PMID:15654758 RGD MGI:MGI:3850619 PMID:15654758 phosphatidylcholine-sterol O-acyltransferase activator activity   IEA Ensembl:ENSMUSP00000133302 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 phosphatidylcholine-sterol O-acyltransferase activator activity   ISO RGD:736378 1624291 PMID:15654758 RGD PMID:15654758 phospholipid binding   IDA   1626397   RGD   phospholipid binding   ISO RGD:736378 1624291 PMID:4066713 RGD PMID:4066713 protein binding   ISO RGD:736378 1624291 UniProtKB:P50502 RGD PMID:21163940 protein binding   ISO RGD:736378 1624291 UniProtKB:P10636 RGD PMID:7972031 protein binding   ISO RGD:736378 1624291 UniProtKB:O75069 RGD PMID:21593558 protein heterodimerization activity   ISO RGD:736378 1624291 UniProtKB:P02652 RGD PMID:8245722 protein heterodimerization activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 protein homodimerization activity   ISO RGD:736378 1624291 PMID:8245722 RGD PMID:8245722 protein homodimerization activity   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 tau protein binding   ISO RGD:736378 1624291 UniProtKB:P10636 RGD PMID:7566652 tau protein binding   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle receptor binding   ISO RGD:736378 1624291 UniProtKB:Q14114 RGD PMID:12950167 very-low-density lipoprotein particle receptor binding   IEA Ensembl:ENSP00000252486 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle receptor binding   ISO RGD:736378 1624291 PMID:1384047 RGD PMID:1384047 Molecular Pathway Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) altered lipoprotein metabolic pathway   ISS   1578416   RGD   Alzheimer disease pathway   IEA RGD:2138 6907045   KEGG rno:05010 lipoprotein metabolic pathway   ISS   1578416   RGD   External Database Links KEGG Pathway Alzheimer's disease Disease Annotations Alzheimer Disease  (IEA,IEP,ISS) Alzheimer disease type 2  (ISS) Aortic Aneurysm, Abdominal  (ISS) Atherosclerosis  (ISS) Bile Duct Neoplasms  (ISS) Brain Injuries  (IEA) Carcinoma, Hepatocellular  (ISS) Cardiomyopathy, Dilated  (ISS) Cardiovascular Diseases  (IEA) Carotid Artery Diseases  (IEA) Cerebral Hemorrhage  (ISS) Cerebral Infarction  (ISS) Cerebrovascular Disorders  (ISS) Cholelithiasis  (ISS) Cholestasis  (ISS) Coronary Artery Disease  (IEA,ISS) Coronary Disease  (ISS) Craniocerebral Trauma  (ISS) Dementia  (IEA) Diabetes Mellitus, Experimental  (IEP) Diabetes Mellitus, Type 1  (IEA,ISS) Diabetes Mellitus, Type 2  (IEA,ISS) Diabetic Nephropathies  (ISS) Endotoxemia  (ISS) Gallbladder Neoplasms  (ISS) Glaucoma  (IEA) Glomerulonephritis  (ISS) Glomerulonephritis, Membranous  (IEP) Glomerulosclerosis  (IED,IEP) Hypercholesterolemia  (ISS) Hyperlipidemia, Familial Combined  (ISS) Hyperlipidemias  (IEA,IED) Hyperlipoproteinemia Type III  (IEA,ISS) Hyperlipoproteinemias  (ISS) Hypertension  (IEA,IEP) Hypertriglyceridemia  (ISS) Hyperuricemia  (ISS) Infarction, Middle Cerebral Artery  (IED) Kidney Failure, Chronic  (ISS) Lipoprotein Glomerulopathy  (ISS) Macular Degeneration  (IEA,ISS) Macular Degeneration, Age-Related, 1  (ISS) Memory Disorders  (ISS) Multiple Sclerosis  (IEA,ISS) Myocardial Infarction  (IEA,ISS) Myocardial Ischemia  (ISS) Non-alcoholic Fatty Liver Disease  (IED) Obesity  (IEA,ISS) Pancreatic Neoplasms  (IEP) Peripheral Nerve Injuries  (IEP,ISS) Sea-Blue Histiocyte Syndrome  (ISS) Sleep Apnea Syndromes  (IEA) Splenomegaly  (ISS) Stroke  (IEA) Subarachnoid Hemorrhage  (IEA) Vascular System Injuries  (IEP,ISS) Venous Thrombosis  (ISS) Gene-Chemical Interaction Annotations (3S,5R)-fluvastatin  (ISO) (S)-nicotine  (ISO) 11-dehydro-thromboxane B2  (ISO) 17alpha-ethynylestradiol  (EXP,ISO) 17beta-hydroxy-5alpha-androstan-3-one  (ISO) 2,2',5,5'-tetrachlorobiphenyl  (ISO) 2,3,7,8-tetrachlorodibenzodioxine  (ISO) 2-amino-2-deoxy-D-glucopyranose  (ISO) 2-butoxyethanol  (ISO) 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP,ISO) 3H-1,2-dithiole-3-thione  (EXP) 6-oxo-prostaglandin F1alpha  (ISO) 7,12-dimethyltetraphene  (ISO) 8-epi-prostaglandin F2alpha  (ISO) acenocoumarol  (ISO) acetylcholine  (ISO) acetylsalicylic acid  (ISO) acrolein  (ISO) aflatoxin B1  (ISO) aldehydo-D-glucosamine  (ISO) all-trans-retinoic acid  (ISO) amiodarone  (EXP) ammonium chloride  (EXP) arachidonic acid  (ISO) arsenic atom  (ISO) benzo[a]pyrene  (ISO) beta-D-glucosamine  (ISO) bezafibrate  (EXP,ISO) calcium atom  (EXP,ISO) calcium(0)  (EXP,ISO) capsaicin  (ISO) cetrorelix  (ISO) chloroquine  (EXP) cholesterol  (ISO) cisplatin  (ISO) clofibric acid  (EXP) cobalt atom  (ISO) copper atom  (EXP) copper(0)  (EXP) copper(2+) sulfate  (ISO) cyclophosphamide  (ISO) cyclosporin A  (ISO) cypermethrin  (EXP,ISO) desogestrel  (ISO) dexamethasone  (ISO) diarsenic trioxide  (ISO) diethylstilbestrol  (ISO) dipyridamole  (ISO) diuron  (EXP) doxorubicin  (EXP,ISO) elemental selenium  (ISO) enalapril  (ISO) ethanolamine  (EXP) felodipine  (ISO) flutamide  (EXP) folic acid  (ISO) gemfibrozil  (EXP) genistein  (ISO) hydrazine  (EXP) hydrogen peroxide  (EXP) indomethacin  (ISO) iron atom  (ISO) isotretinoin  (ISO) kaempferol  (ISO) kainic acid  (ISO) ketamine  (EXP,ISO) L-ascorbic acid  (EXP) lansoprazole  (ISO) lead diacetate  (ISO) lead(0)  (ISO) mercury atom  (ISO) mercury(0)  (ISO) mono(2-ethylhexyl) phthalate  (EXP) morphine  (EXP) N-nitrosodiethylamine  (EXP) N-tosyl-L-phenylalanyl chloromethyl ketone  (ISO) nickel sulfate  (ISO) nimesulide  (ISO) ochratoxin A  (EXP) ozone  (ISO) paracetamol  (EXP,ISO) paricalcitol  (ISO) perfluorooctanoic acid  (ISO) phenobarbital  (EXP) phenylephrine  (ISO) phenytoin  (ISO) phosphorus atom  (ISO) phosphorus(.)  (ISO) pirinixic acid  (EXP) quercetin  (ISO) rel-(3R,5S)-fluvastatin  (ISO) resveratrol  (EXP,ISO) retinyl acetate  (ISO) rosiglitazone  (ISO) selenium atom  (ISO) simvastatin  (EXP,ISO) sodium dichromate  (EXP) streptozocin  (EXP,ISO) superoxide  (ISO) tamoxifen  (ISO) tert-butyl hydroperoxide  (EXP,ISO) testosterone enanthate  (ISO) tetrachloromethane  (EXP) trans-resveratrol  (EXP,ISO) trimellitic anhydride  (ISO) troglitazone  (ISO) valsartan  (ISO) vanadyl sulfate  (EXP) vitamin K  (ISO) zearalenone  (ISO) Gene Ontology Annotations Biological Process aging  (IDA) artery morphogenesis  (IEA,ISO) axon regeneration  (ISO) cardiovascular system development  (ISO) cellular calcium ion homeostasis  (IEA,ISO) cellular response to cholesterol  (IEP) cellular response to growth factor stimulus  (IEP) cellular response to interleukin-1  (IEP) cGMP-mediated signaling  (IEA,ISO) cholesterol catabolic process  (IEA,ISO) cholesterol efflux  (IEA,ISO) cholesterol homeostasis  (IEA,ISO) cholesterol metabolic process  (ISO) chylomicron remnant clearance  (IEA,ISO) G-protein coupled receptor signaling pathway  (IEA,ISO) high-density lipoprotein particle assembly  (IEA,ISO) high-density lipoprotein particle clearance  (IEA,ISO) high-density lipoprotein particle remodeling  (IEA,ISO) induction of apoptosis  (IEA) lipid homeostasis  (ISO) lipid metabolic process  (ISO) lipid transport  (IDA) lipoprotein biosynthetic process  (IEA,ISO) lipoprotein catabolic process  (IEA,ISO) lipoprotein metabolic process  (IDA,ISO) low-density lipoprotein particle remodeling  (IEA,ISO) maintenance of location in cell  (IEA,ISO) negative regulation of apoptotic process  (ISO) negative regulation of blood coagulation  (ISO) negative regulation of blood vessel endothelial cell migration  (IEA,ISO) negative regulation of cholesterol biosynthetic process  (IEA,ISO) negative regulation of endothelial cell proliferation  (IEA,ISO) negative regulation of inflammatory response  (IEA,ISO) negative regulation of MAP kinase activity  (IEA,ISO) negative regulation of neuron apoptotic process  (IDA) negative regulation of platelet activation  (IEA,ISO) neuron projection regeneration  (TAS) nitric oxide mediated signal transduction  (IEA,ISO) oligodendrocyte differentiation  (IEP) peripheral nervous system axon regeneration  (IEP) phospholipid efflux  (IEA,ISO) positive regulation of axon extension  (IDA) positive regulation of catalytic activity  (ISO) positive regulation of cGMP biosynthetic process  (IEA,ISO) positive regulation of cholesterol efflux  (IEA,ISO) positive regulation of cholesterol esterification  (IEA,ISO) positive regulation of low-density lipoprotein particle receptor catabolic process  (IEA,ISO) positive regulation of membrane protein ectodomain proteolysis  (IEA,ISO) positive regulation of nitric-oxide synthase activity  (IEA,ISO) protein localization  (ISO) receptor-mediated endocytosis  (IEA,ISO) regulation of Cdc42 protein signal transduction  (IEA,ISO) regulation of gene expression  (IEA,ISO) response to dietary excess  (IEA,ISO) response to ethanol  (IEP) response to insulin stimulus  (IEP) response to oxidative stress  (IEA,ISO) response to retinoic acid  (IEP) reverse cholesterol transport  (IEA,ISO) triglyceride metabolic process  (IEA,ISO) vasodilation  (IEA,ISO) very-low-density lipoprotein particle clearance  (IEA,ISO) very-low-density lipoprotein particle remodeling  (IEA,ISO) Cellular Component chylomicron  (IEA,ISO) cytoplasm  (IDA) dendrite  (IDA) early endosome  (IDA) extracellular space  (IDA,ISO) extrinsic to external side of plasma membrane  (IDA) Golgi apparatus  (IDA) high-density lipoprotein particle  (IEA,ISO) intermediate-density lipoprotein particle  (IEA,ISO) late endosome  (IDA) low-density lipoprotein particle  (IEA,ISO) microtubule  (IDA) neuronal cell body  (IDA) plasma membrane  (IDA) very-low-density lipoprotein particle  (IEA,ISO) Molecular Function antioxidant activity  (IEA,ISO) beta-amyloid binding  (IDA,ISO,ISS) cholesterol transporter activity  (IEA,ISO) heparin binding  (IEA,ISO) hydroxyapatite binding  (IDA) identical protein binding  (ISO) lipid binding  (ISO) lipid transporter activity  (IDA,ISO) lipoprotein particle binding  (IEA,ISO) low-density lipoprotein particle receptor binding  (IEA,ISO) metal chelating activity  (IEA,ISO) phosphatidylcholine-sterol O-acyltransferase activator activity  (IEA,ISO) phospholipid binding  (IDA,ISO) protein binding  (ISO) protein heterodimerization activity  (IEA,ISO) protein homodimerization activity  (IEA,ISO) tau protein binding  (IEA,ISO) very-low-density lipoprotein particle receptor binding  (IEA,ISO) Molecular Pathway Annotations altered lipoprotein metabolic pathway  (ISS) Alzheimer disease pathway  (IEA) lipoprotein metabolic pathway  (ISS) External Database Links KEGG Pathway Alzheimer's disease References - curated 1. Andreotti G, etal., Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):525-34. Epub 2008 Feb 22. 2. Arold S, etal., Acta Neuropathol. 2012 Jan;123(1):39-52. Epub 2011 Oct 22. 3. Bagavant H, etal., Am J Pathol. 2011 Aug;179(2):651-60. Epub 2011 Jun 14. 4. Bartres-Faz D, etal., Neurogenetics. 2001 Oct;3(4):215-9. 5. Becker KG, etal., Nat Genet 2004 May;36(5):431-2. 6. Bisgaier CL, etal., J Biol Chem. 1989 Jan 15;264(2):862-6. 7. Boyles JK, etal., J Biol Chem. 1990 Oct 15;265(29):17805-15. 8. Bugnicourt JM, etal., Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1143-52. Epub 2011 Jun 24. 9. Cardona F, etal., J Clin Endocrinol Metab. 2005 May;90(5):2972-5. Epub 2005 Feb 15. 10. Cazzin C, etal., Mol Biol Rep. 2011 Feb;38(2):983-90. Epub 2010 Jun 10. 11. Chang XX, etal., Lipids Health Dis. 2012 Jul 4;11(1):86. 12. Chen Q, etal., Atherosclerosis. 2003 Jul;169(1):159-67. 13. Chmielewski M, etal., Nephrol Dial Transplant. 2011 Oct;26(10):3325-31. Epub 2011 Feb 28. 14. Corella D and Ordovas JM, Annu Rev Nutr. 2005;25:341-90. 15. Dahan S, etal., J Cell Biol. 1994 Dec;127(6 Pt 2):1859-69. 16. Daugherty A, etal., J Clin Invest. 2000 Jun;105(11):1605-12. 17. Diaz JA, etal., J Vasc Surg. 2012 Mar;55(3):815-22. Epub 2011 Nov 25. 18. Feussner G, etal., Eur J Clin Invest. 1992 Sep;22(9):599-608. 19. Frikke-Schmidt R, etal., Hum Genet. 2007 Feb;120(6):865-877. Epub 2006 Sep 28. 20. Gao J, etal., Diabetes. 2007 Jan;56(1):24-33. 21. Gerdes LU, etal., Br J Surg. 2000 Jun;87(6):760-5. 22. GOA data from the GO Consortium 23. Gronborg M, etal., Mol Cell Proteomics. 2006 Jan;5(1):157-71. Epub 2005 Oct 8. 24. Hayashi H, etal., J Neurosci. 2007 Feb 21;27(8):1933-41. 25. Hogh P, etal., Acta Neurol Scand. 2007 Apr;115(4):248-53. 26. Horsburgh K and Nicoll JA, Neuropathol Appl Neurobiol. 1996 Aug;22(4):342-9. 27. Huang NF, etal., Am J Transl Res. 2011 Feb;3(2):139-48. Epub 2010 Nov 21. 28. Ignatius MJ, etal., Proc Natl Acad Sci U S A. 1986 Feb;83(4):1125-9. 29. Ishigaki Y, etal., J Biol Chem. 2000 Oct 6;275(40):31269-73. 30. James ML, etal., J Stroke Cerebrovasc Dis. 2009 Mar-Apr;18(2):144-9. 31. Jurkovicova D, etal., Gen Physiol Biophys. 2006 Mar;25(1):3-10. 32. Kamada H, etal., J Neurosci Res 2003 Aug 15;73(4):545-56. 33. Kaneko H, etal., Anal Biochem. 2011 Nov 15;418(2):276-85. Epub 2011 Jul 26. 34. KEGG 35. Kim SW, etal., Proteomics. 2006 Oct;6(19):5291-302. 36. LaDu MJ, etal., Biochim Biophys Acta. 2012 Feb;1821(2):295-302. Epub 2011 Nov 23. 37. Li FQ, etal., J Pharmacol Exp Ther. 2010 Jul;334(1):106-15. Epub 2010 Apr 20. 38. Li Z and Fengxian H, Ren Fail. 2011;33(2):124-30. 39. Liu L, etal., J Neuroinflammation. 2011 Dec 15;8:175. 40. Liu M, etal., J Neurosci Methods. 2012 Jul 30;209(1):106-12. Epub 2012 Jun 9. 41. Lopez-Parra V, etal., J Am Soc Nephrol. 2012 Sep;23(9):1518-27. Epub 2012 Aug 2. 42. Marmillot P, etal., Alcohol. 2001 Nov;25(3):195-200. 43. Marques FZ, etal., Hypertension. 2010 Aug;56(2):319-24. Epub 2010 Jun 28. 44. Matsuo M, etal., Biochim Biophys Acta. 2011 Jan;1811(1):31-8. Epub 2010 Oct 30. 45. MGD data from the GO Consortium 46. Miklossy J, etal., Neurobiol Aging. 2008 Oct 23. 47. Mooyaart AL, etal., Diabetologia. 2011 Mar;54(3):544-53. Epub 2010 Dec 3. 48. Mullick AE, etal., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2080-5. 49. Nakano T, etal., J Hepatol. 2011 Aug;55(2):415-25. Epub 2010 Dec 22. 50. NCBI rat LocusLink and RefSeq merged data July 26, 2002 51. Nelissen K, etal., J Neurosci Res. 2012 Jan;90(1):60-71. doi: 10.1002/jnr.22743. Epub 2011 Oct 3. 52. Nishida T, etal., J Biochem. 2009 Dec;146(6):881-6. Epub 2009 Aug 27. 53. Oikawa S, etal., J Am Soc Nephrol. 1997 May;8(5):820-3. 54. Pei WD, etal., Circ J. 2006 Dec;70(12):1606-10. 55. Pipeline to import KEGG annotations from KEGG into RGD Pathway Ontology 56. Raman KG, etal., J Vasc Surg. 2011 Mar;53(3):754-63. Epub 2010 Dec 15. 57. Reiber I, etal., J Nutr Biochem. 2003 Jul;14(7):394-400. 58. Rensen PC, etal., J Clin Invest. 1997 May 15;99(10):2438-45. 59. RGD automated data pipeline 60. RGD automated import pipeline for gene-chemical interactions 61. RGD Automated Pipelines 62. Ritorto MS and Borlak J, J Proteome Res. 2011 Jul 1;10(7):3012-30. Epub 2011 Jun 6. 63. Ruscher K, etal., J Cereb Blood Flow Metab. 2009 Nov;29(11):1796-805. Epub 2009 Jul 22. 64. Sabaretnam T, etal., Age (Dordr). 2009 Oct 7. 65. Scacchi R, etal., Neurosci Lett. 1999 Jan 4;259(1):33-6. 66. Schmitz F, etal., Eur J Clin Invest. 2007 Feb;37(2):106-8. 67. Soggiu A, etal., Acta Diabetol. 2012 Jun 8. 68. Strausberg RL, etal., Proc Natl Acad Sci U S A 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11. 69. Takahashi H, etal., Acta Paediatr Jpn. 1996 Dec;38(6):634-9. 70. Tentative Sequence Data IDs. TIGR Gene Index, Rat Data 71. Viitanen L, etal., J Mol Med. 2001 Dec;79(12):732-7. Epub 2001 Jul 25. 72. Wang L, etal., Kidney Int. 2012 Jul 11. doi: 10.1038/ki.2012.244. 73. Williams DL, etal., J Lipid Res. 1995 Apr;36(4):745-58. 74. Yamada Y, etal., Mol Genet Metab. 2004 Apr;81(4):282-90. 75. Yamaguchi S, etal., Int J Mol Med. 2006 Nov;18(5):871-83. 76. Yan L, etal., J Proteome Res. 2009 Jan;8(1):142-8. 77. Yue L and Mazzone T, J Lipid Res. 2011 Mar;52(3):489-98. Epub 2010 Dec 16. 78. Zhang SH, etal., Science 1992 Oct 16;258(5081):468-71. 79. Zhou TB, etal., Histol Histopathol. 2012 Feb;27(2):249-56. 80. Zhou TB, etal., Vascul Pharmacol. 2011 Nov-Dec;55(5-6):169-77. Epub 2011 Sep 2. References - uncurated PubMed 12870266   15489334   15866734   16376010   16497717   16524875   16802110   17012232   17126342   18288929   18360691   18559657   19362542   19382209   19414061   19717566   20456011   22674573   23103361   3020048   3797247   6190813   7766086 RGD Disease Portals Apoe has been annotated in the following RGD Disease Portals. Biological Process Cancer Diseases Cancer Pathways Biological Process Cardiovascular Diseases Biological Process Diabetes Diseases Diabetes Pathways Biological Process Immune and Inflammatory Diseases Immune and Inflammatory Pathways Biological Process Neurological Diseases Neurological Pathways Biological Process Obesity Diseases Obesity Pathways Biological Process Respiratory Diseases Respiratory Pathways Genomics Comparative Map Data Apoe   (Rattus norvegicus) Map Chr Position Strand Source Rat Cytogenetic Map 1 q21   NCBI RGSC Genome Assembly v5.0 1 81,878,372 - 81,881,125 - NCBI RGSC Genome Assembly v3.4 1 79,003,634 - 79,006,387 - NCBI Rat Celera Assembly 1 73,813,122 - 73,815,875 - NCBI Genome Assembly 3.1 1 79,081,854 - 79,083,684 - NCBI APOE   (Homo sapiens) Map Chr Position Strand Source Human Alternate Assembly CHM1_1 19 45,599,171 - 45,602,875 + NCBI Human Genome Assembly HuRef 19 41,839,825 - 41,843,436 + NCBI Human Genome Assembly GRCh37 19 45,409,039 - 45,412,650 + NCBI Human Genome Assembly Build 36 19 50,100,879 - 50,104,490 + NCBI Human Cytogenetic Map 19 q13.2   NCBI Human Genome Assembly 19 50,100,878 - 50,104,489   NCBI Apoe   (Mus musculus) Map Chr Position Strand Source Mouse Genome Assembly GRCm38 7 19,696,244 - 19,699,166 - NCBI Mouse cM Map 7 9.94   NCBI Mouse Celera Assembly 7 17,102,329 - 17,105,251 - NCBI Mouse Genome Assembly Build 37 7 20,281,593 - 20,284,515 - NCBI Mouse Genome Assembly Build 36.1 7 20,281,621 - 20,284,381 - NCBI Mouse Cytogenetic Map 7 A3   NCBI Position Markers RH94767   Map Chr Position Strand Source Rat Cytogenetic Map 1 q21   UniSTS RGSC Genome Assembly v5.0 1 81,878,186 - 81,878,420   UniSTS RGSC Genome Assembly v3.4 1 79,003,448 - 79,003,682   UniSTS Rat Celera Assembly 1 73,812,936 - 73,813,170   UniSTS RH94459   Map Chr Position Strand Source Rat Cytogenetic Map 1 q21   UniSTS RGSC Genome Assembly v5.0 1 81,878,181 - 81,878,333   UniSTS RGSC Genome Assembly v3.4 1 79,003,443 - 79,003,595   UniSTS Rat Celera Assembly 1 73,812,931 - 73,813,083   UniSTS NoName   Map Chr Position Strand Source Rat Cytogenetic Map 1 q21   UniSTS RGSC Genome Assembly v5.0 1 81,879,177 - 81,879,640   UniSTS Rat Celera Assembly 1 73,813,927 - 73,814,390   UniSTS QTLs in Region (RGSC Genome Assembly v3.4) The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer RGD ID Symbol Name LOD P Value Trait Sub Trait Chr Start Stop Species 631688 Hcas2 Hepatocarcinoma susceptibility QTL 2 3 .0001 Liver tumor susceptibility nodule number 1 6253946 116153262 Rat 2313062 Bmd73 Bone mineral density QTL 73 3.9 .0001 Bone mineral density 1 11859997 81947972 Rat 2313065 Bss67 Bone structure and strength QTL 67 3.1 .0001 Bone structure 1 11859997 81947972 Rat 2313069 Bss68 Bone structure and strength QTL 68 2.9 .0001 Bone structure 1 11859997 81947972 Rat 2313075 Bss66 Bone structure and strength QTL 66 3.4 .0001 Bone structure 1 11859997 81947972 Rat 2313077 Bss69 Bone structure and strength QTL 69 3.5 .0001 Bone strength 1 11859997 81947972 Rat 2313092 Bmd72 Bone mineral density QTL 72 2.5 .0001 Bone mineral density 1 11859997 81947972 Rat 2313097 Bss70 Bone structure and strength QTL 70 3.5 .0001 Bone strength 1 11859997 81947972 Rat 631495 Bp96 Blood pressure QTL 96 4.52 Blood pressure systolic 1 22842898 102532417 Rat 1358359 Sradr1 Stress Responsive Adrenal Weight QTL 1 4.74 Hypothalamic-pituitary-adrenal axis adrenal gland weight 1 28716493 124749065 Rat 2313051 Bss57 Bone structure and strength QTL 57 3.7 .0001 Bone strength 1 37646940 119780561 Rat 2313059 Bss55 Bone structure and strength QTL 55 3.2 .0001 Bone structure 1 37646940 119780561 Rat 2313072 Bss53 Bone structure and strength QTL 53 4.3 .0001 Bone structure 1 37646940 119780561 Rat 2313078 Bss54 Bone structure and strength QTL 54 3.5 .0001 Bone structure 1 37646940 119780561 Rat 2313094 Bss58 Bone structure and strength QTL 58 3.7 .0001 Bone strength 1 37646940 119780561 Rat 2313098 Bmd70 Bone mineral density QTL 70 3.6 .0001 Bone mineral density 1 37646940 119780561 Rat 2313099 Bss56 Bone structure and strength QTL 56 2.4 .0001 Bone structure 1 37646940 119780561 Rat 2302059 Pia36 Pristane induced arthritis QTL 36 3.8 .001 Joint/bone inflammation pristane induced 1 41645883 86645883 Rat 2313402 Anxrr24 Anxiety related response QTL 24 Anxiety response domestication 1 43426139 146971983 Rat 4889962 Bss94 Bone structure and strength QTL 94 3.8 Bone structure 1 43840481 81947972 Rat 1578649 Bmd8 Bone mineral density QTL 8 4.9 Bone mineral density femoral neck trabecular vBMD 1 43872710 88872710 Rat 1578654 Bss10 Bone structure and strength QTL 10 4 Bone structure femoral neck cortical area 1 43872710 162735928 Rat 634314 Niddm44 Non-insulin dependent diabetes mellitus QTL 44 Glucose level 1 43872827 204280278 Rat 4889919 Bss86 Bone structure and strength QTL 86 4.1 Bone structure 1 48777689 81947972 Rat 4889929 Bss87 Bone structure and strength QTL 87 6.7 Bone structure 1 48777689 81947972 Rat 6903308 Scl36 Serum cholesterol QTL 36 2 .0125 Lipid level cholesterol level 1 53013200 90306478 Rat 2298545 Neuinf8 Neuroinflammation QTL 8 2.9 Neuroinflammation 1 55083934 154002647 Rat 2300324 Fetw1 Fetal weight QTL 1 12.1 .005 Fetal weight 1 55540384 100540384 Rat 2300164 Bmd44 Bone mineral density QTL 44 5.4 .0001 Bone mineral density 1 56601368 101601368 Rat 1300121 Hrtrt1 Heart rate QTL 1 3.7 Heart rate salt-loaded 1 64744882 116153262 Rat 631512 Scl6 Serum cholesterol level QTL 6 9.6 Lipid level cholesterol 1 71659707 90282193 Rat 1549903 Bp267 Blood pressure QTL 267 Blood pressure systolic, nighttime 1 77541583 106445306 Rat Sequence Nucleotide Sequences Nucleotide RefSeqs NM_001270681 (Get FASTA) Search GEO for Microarray Profiles   NM_001270682 (Get FASTA) Search GEO for Microarray Profiles   NM_001270683 (Get FASTA) Search GEO for Microarray Profiles   NM_001270684 (Get FASTA) Search GEO for Microarray Profiles   NM_138828 (Get FASTA) Search GEO for Microarray Profiles GenBank Nucleotide AABR06003890 (Get FASTA) Search GEO for Microarray Profiles   AAHX01004212 (Get FASTA) Search GEO for Microarray Profiles   BC060313 (Get FASTA) Search GEO for Microarray Profiles   BC086581 (Get FASTA) Search GEO for Microarray Profiles   CH473979 (Get FASTA) Search GEO for Microarray Profiles   FQ209421 (Get FASTA) Search GEO for Microarray Profiles   FQ209426 (Get FASTA) Search GEO for Microarray Profiles   FQ209428 (Get FASTA) Search GEO for Microarray Profiles   FQ209457 (Get FASTA) Search GEO for Microarray Profiles   FQ209625 (Get FASTA) Search GEO for Microarray Profiles   FQ209879 (Get FASTA) Search GEO for Microarray Profiles   FQ209926 (Get FASTA) Search GEO for Microarray Profiles   FQ210262 (Get FASTA) Search GEO for Microarray Profiles   FQ210410 (Get FASTA) Search GEO for Microarray Profiles   FQ210854 (Get FASTA) Search GEO for Microarray Profiles   FQ211250 (Get FASTA) Search GEO for Microarray Profiles   FQ212760 (Get FASTA) Search GEO for Microarray Profiles   FQ212769 (Get FASTA) Search GEO for Microarray Profiles   FQ213060 (Get FASTA) Search GEO for Microarray Profiles   FQ213396 (Get FASTA) Search GEO for Microarray Profiles   FQ213533 (Get FASTA) Search GEO for Microarray Profiles   FQ213898 (Get FASTA) Search GEO for Microarray Profiles   FQ214072 (Get FASTA) Search GEO for Microarray Profiles   FQ214282 (Get FASTA) Search GEO for Microarray Profiles   FQ218386 (Get FASTA) Search GEO for Microarray Profiles   FQ218473 (Get FASTA) Search GEO for Microarray Profiles   FQ218485 (Get FASTA) Search GEO for Microarray Profiles   FQ218540 (Get FASTA) Search GEO for Microarray Profiles   FQ218699 (Get FASTA) Search GEO for Microarray Profiles   FQ218754 (Get FASTA) Search GEO for Microarray Profiles   FQ218898 (Get FASTA) Search GEO for Microarray Profiles   FQ218953 (Get FASTA) Search GEO for Microarray Profiles   FQ219009 (Get FASTA) Search GEO for Microarray Profiles   FQ219124 (Get FASTA) Search GEO for Microarray Profiles   FQ219144 (Get FASTA) Search GEO for Microarray Profiles   FQ219202 (Get FASTA) Search GEO for Microarray Profiles   FQ219319 (Get FASTA) Search GEO for Microarray Profiles   FQ219432 (Get FASTA) Search GEO for Microarray Profiles   FQ219448 (Get FASTA) Search GEO for Microarray Profiles   FQ219475 (Get FASTA) Search GEO for Microarray Profiles   FQ219490 (Get FASTA) Search GEO for Microarray Profiles   FQ219516 (Get FASTA) Search GEO for Microarray Profiles   FQ219534 (Get FASTA) Search GEO for Microarray Profiles   FQ219700 (Get FASTA) Search GEO for Microarray Profiles   FQ219711 (Get FASTA) Search GEO for Microarray Profiles   FQ220125 (Get FASTA) Search GEO for Microarray Profiles   FQ220532 (Get FASTA) Search GEO for Microarray Profiles   FQ220683 (Get FASTA) Search GEO for Microarray Profiles   FQ220752 (Get FASTA) Search GEO for Microarray Profiles   FQ220879 (Get FASTA) Search GEO for Microarray Profiles   FQ221856 (Get FASTA) Search GEO for Microarray Profiles   FQ223299 (Get FASTA) Search GEO for Microarray Profiles   FQ229186 (Get FASTA) Search GEO for Microarray Profiles   FQ229201 (Get FASTA) Search GEO for Microarray Profiles   FQ229530 (Get FASTA) Search GEO for Microarray Profiles   FQ229565 (Get FASTA) Search GEO for Microarray Profiles   FQ229650 (Get FASTA) Search GEO for Microarray Profiles   FQ229759 (Get FASTA) Search GEO for Microarray Profiles   FQ229950 (Get FASTA) Search GEO for Microarray Profiles   FQ230084 (Get FASTA) Search GEO for Microarray Profiles   FQ231375 (Get FASTA) Search GEO for Microarray Profiles   J00705 (Get FASTA) Search GEO for Microarray Profiles   J02582 (Get FASTA) Search GEO for Microarray Profiles   X04979 (Get FASTA) Search GEO for Microarray Profiles Reference Sequences RefSeq Acc Id: NM_138828 RefSeq Status: VALIDATED Type: CODING Protein Acc Id: NP_620183 Peptide Label: precursor Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 1 81,878,372 - 81,881,125 - NCBI RGSC Genome Assembly v3.4 1 79,003,634 - 79,006,387 - RGD Rat Celera Assembly 1 73,813,122 - 73,815,875 - RGD Protein Sequences Protein RefSeqs NP_001257610 (Get FASTA)   NP_001257611 (Get FASTA)   NP_001257612 (Get FASTA)   NP_001257613 (Get FASTA)   NP_620183 (Get FASTA) GenBank Protein AAA40755 (Get FASTA)   AAA40756 (Get FASTA)   AAH60313 (Get FASTA)   AAH86581 (Get FASTA)   CAA28650 (Get FASTA)   EDM08150 (Get FASTA)   EDM08151 (Get FASTA)   EDM08152 (Get FASTA)   EDM08153 (Get FASTA)   EDM08154 (Get FASTA)   EDM08155 (Get FASTA)   EDM08156 (Get FASTA)   EDM08157 (Get FASTA)   EDM08158 (Get FASTA)   EDM08159 (Get FASTA)   EDM08160 (Get FASTA)   EDM08161 (Get FASTA)   EDM08162 (Get FASTA)   EDM08163 (Get FASTA)   EDM08164 (Get FASTA)   EDM08165 (Get FASTA)   EDM08166 (Get FASTA)   EDM08167 (Get FASTA)   EDM08168 (Get FASTA)   EDM08169 (Get FASTA)   P02650 (Get FASTA) Promoters RGD ID: 6849578 Promoter ID: EP36008 Type: single initiation site Name: RN_APE Description: Apolipoprotein E, APOE gene. SO ACC ID: SO:0000170 Source: EPD (Eukaryotic Promoter Database, http://epd.vital-it.ch/) Notes: homology_group=Homology group 208; Mammalian apolipoprotein E Tissues & Cell Lines: liver > brain, adrenal gland Experiment Methods: Nuclease protection; experiments performed with closely related; gene Position: Map Chr Position Strand Source RGSC Genome Assembly v3.4 1 79,006,416 - 79,006,476   EPD Strain Variation Strain Sequence Variants ACI/Eur (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 ACI/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN-Lx (ICL) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: SOLID Secondary Analysis: BWA, GATK, Samtools Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: MC-A654-5QB00 BN-Lx (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/NHsdMcwi (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/SsN (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Buf/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) COP/Crl (MCW & UW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Univiersity of Wisconsin (Jim Shull) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 Breeder: Charles River Grant Information: NIH (CA77876) F344/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHH/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 FHH/EurMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHL/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 GH/OmrMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 LE/Stm (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Dr. Tadao Serikawa, Kyoto Japan. Grant Information: EURATRANS (HEALTH-F4-2010-241504) M520/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) MR/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHR/Olalpcv (ICL) Visual CSV TAB Printer Sequenced By: Imperial College London (Dr Timothy Aitman) University of British Columbia (Dr. Steven Jones) Platform: Illumina Hi-seq 2000 and GAII Secondary Analysis: BWA, GATK Breeder: Institute of Physiology, Academy of Sciences of the Czech Republic, Prague Grant Information: LSHG-CT-2005-019015, HEALTH-F4-2010-241504 SHR/Olalpcv (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: Illumina Secondary Analysis: GATK Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHRSP/Gcrc (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruch Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: University of Glasgow, Anna Dominiczak Grant Information: EURATRANS (HEALTH-F4-2010-241504) SR/JrHsd (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Breeder: Harlan SS/JrHsdMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Grant Information: R01 HL089930 SS/JrHsdMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) WKY/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) WN/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Additional Information External Database Links Database Acc Id Source(s) Ensembl Genes ENSRNOG00000018454 ENTREZGENE, UniProtKB/Swiss-Prot Ensembl Protein ENSRNOP00000050968 ENTREZGENE, UniProtKB/Swiss-Prot Ensembl Transcript ENSRNOT00000041891 ENTREZGENE, UniProtKB/Swiss-Prot Entrez Gene 25728 ENTREZGENE Germonline ENSRNOG00000018454 UniProtKB/Swiss-Prot HomoloGene Group ID 30951 ENTREZGENE IMAGE_CLONE IMAGE:6919048 IMAGE-MGC_LOAD   IMAGE:7307758 IMAGE-MGC_LOAD InterPro ApoA/E_ApoLp UniProtKB/Swiss-Prot   ApoA1_A4_E UniProtKB/Swiss-Prot IPI IPI00190701 UniProtKB/Swiss-Prot KEGG Report rno:25728 ENTREZGENE, UniProtKB/Swiss-Prot MGC_CLONE MGC:105323 IMAGE-MGC_LOAD   MGC:72690 IMAGE-MGC_LOAD Pfam Apolipoprotein UniProtKB/Swiss-Prot PharmGKB APOE RGD Superfamily-SCOP SSF47162 UniProtKB/Swiss-Prot TIGR TC204356 UniGene Rn.32351 ENTREZGENE UniProt APOE_RAT UniProtKB/Swiss-Prot   Q6PAH0_RAT UniProtKB/TrEMBL Nomenclature History Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status 2003-04-09 Apoe  apolipoprotein E    Apolipoprotein E,  Name updated 2575 APPROVED 2002-06-10 Apoe  Apolipoprotein E,      Symbol and Name status set to approved 1490 APPROVED RGD Curation Notes Note Type Note Reference gene_disease may act to decrease atherosclerosis by decreasing the penetration of triglyceride-rich particles (TGRPs) into the arterial wall 634663 gene_process plays a role in plasma lipoprotein transport 634663

More on Apoe Entrez Gene Ensembl Gene Genome Browser NCBI Map Viewer Vista Vista + UCSC RGD Object Information RGD ID: 2138 Created: 2000-05-25 Species: Rattus norvegicus Last Modified: 2013-04-16 Status: ACTIVE